Arbutus Biopharma Discounted Cash Flow

The latest DCF fair value for ABUS is $-3. Investors often review this figure alongside Arbutus Biopharma's historical trend and sector peers before judging valuation or financial health.

A DCF fair value of $-3 for Arbutus Biopharma suggests the stock may be overvalued by roughly 157.9% at today's price. That does not mean the market is 'wrong'; it means the model's cash-flow assumptions imply a different intrinsic value. Stress-test the estimate by comparing it with historical valuation ranges and peer multiples.

After noting ABUS's DCF fair value ($-3), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Arbutus Biopharma's DCF fair value against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.